Glaukos Corporation
GKOS
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.68B
Close$
$-44.89
134.2% downside
Current Fair Value
134.2% downsideOvervalued by 134.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.68 Billion |
|---|---|
| Enterprise Value | $7.67 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.28 |
| Beta | 0.82 |
| Outstanding Shares | 58,022,000 |
Return
| Return on Equity | -28.22% |
|---|---|
| Return on Assets | -21.19% |
| Return on Invested Capital | -8.87% |
Valuation & Multiples
| P/E Ratio | -39.84 |
|---|---|
| PEG | -441.64 |
| Price to Sales | 14.58 |
| Price to Book Ratio | 11.93 |
| Enterprise Value to Revenue | 13.92 |
| Enterprise Value to EBIT | -107.58 |
| Enterprise Value to Net Income | -41 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$136.98 M
Average shareholder expectationNext Earnings Call
Expected Date
July 29, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$151.13 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 4.7509▼ 3.32% |
|---|---|
| Total Calls | 164,200▼ 5.47% |
| Total Puts | 780,100▼ 6.13% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 100.83%▲ 1.03% |
|---|---|
| Total Invested | $6.25B▼ 3.00% |
| Investors Holding | 346▲ 5.00% |
ESG Score
No data
About Glaukos Corporation
CEO: Thomas Burns Relevant Senate Committees
Finance
This committee controls Medicare and Medicaid reimbursement policy, which is the single most important factor for the commercial success of Glaukos's products.
Appropriations
The committee allocates discretionary funding for healthcare and research; its decisions directly influence the budgets of agencies like the NIH and the FDA.
Health, Education, Labor, and Pensions
This committee oversees the FDA, which regulates the approval and safety of Glaukos's surgical devices and pharmaceutical products.